Integer Holdings Co. (NYSE:ITGR – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $120.50.
A number of equities analysts recently issued reports on the stock. CL King started coverage on shares of Integer in a research report on Thursday, March 14th. They issued a “buy” rating and a $137.00 target price for the company. KeyCorp raised their price objective on shares of Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a research note on Tuesday, April 9th. Bank of America raised Integer from a “neutral” rating to a “buy” rating and increased their price target for the company from $105.00 to $135.00 in a research note on Monday, April 15th. Finally, Benchmark boosted their price objective on Integer from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, March 28th.
View Our Latest Analysis on ITGR
Institutional Investors Weigh In On Integer
Integer Stock Performance
ITGR stock opened at $111.25 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.71 and a current ratio of 2.80. Integer has a 1 year low of $69.40 and a 1 year high of $123.99. The stock’s fifty day moving average is $112.91 and its two-hundred day moving average is $99.57. The stock has a market capitalization of $3.73 billion, a price-to-earnings ratio of 41.36, a PEG ratio of 1.63 and a beta of 1.10.
Integer (NYSE:ITGR – Get Free Report) last announced its quarterly earnings results on Thursday, February 15th. The medical equipment provider reported $1.39 EPS for the quarter, beating the consensus estimate of $1.34 by $0.05. The company had revenue of $413.15 million for the quarter, compared to analyst estimates of $409.04 million. Integer had a net margin of 5.68% and a return on equity of 10.80%. Integer’s revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.11 earnings per share. On average, research analysts predict that Integer will post 5.31 EPS for the current year.
Integer Company Profile
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
Read More
- Five stocks we like better than Integer
- How to Most Effectively Use the MarketBeat Earnings Screener
- Hasbro’s Management Made All the Right Calls This Quarter
- How to Use the MarketBeat Dividend Calculator
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.